Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright

Biomea Fusion (NASDAQ:BMEA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 379.62% from the stock’s current price.

BMEA has been the topic of several other reports. Wall Street Zen upgraded shares of Biomea Fusion from a “sell” rating to a “hold” rating in a report on Monday, October 5th. Brookline Capital Markets initiated coverage on shares of Biomea Fusion in a research note on Wednesday, October 7th. They issued a “buy” rating for the company. Citigroup restated a “market outperform” rating on shares of Biomea Fusion in a research report on Wednesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.60.

Biomea Fusion Stock Down 33.8%

BMEA traded down $0.43 during trading on Wednesday, reaching $0.83. The company had a trading volume of 11,672,629 shares, compared to its average volume of 1,475,090. The business has a 50 day simple moving average of $1.53 and a 200-day simple moving average of $1.47. The stock has a market cap of $60.45 million, a P/E ratio of -2.88 and a beta of -0.28. Biomea Fusion has a 52 week low of $0.80 and a 52 week high of $2.24.

Biomea Fusion (NASDAQ:BMEA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. As a group, equities research analysts expect that Biomea Fusion will post -0.71 EPS for the current fiscal year.

Institutional Trading of Biomea Fusion

Large investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new position in Biomea Fusion in the 2nd quarter worth about $64,000. BlackRock Inc. bought a new stake in Biomea Fusion during the 2nd quarter valued at about $1,052,000. GSA Capital Partners LLP bought a new stake in Biomea Fusion during the 2nd quarter valued at about $318,000. Rathbones Group PLC purchased a new stake in Biomea Fusion in the 1st quarter valued at about $57,000. Finally, Renaissance Technologies LLC boosted its position in Biomea Fusion by 174.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock valued at $2,009,000 after buying an additional 834,179 shares during the period. 96.72% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Analyst support remains bullish. Citizens JMP reaffirmed its “Market Outperform” rating and assigned a $7 price target, while HC Wainwright reaffirmed its “Buy” rating with a $4 target. These targets imply substantial potential upside from recent trading levels, but they remain analyst estimates rather than guaranteed outcomes.
• Positive Sentiment: BMF-650 demonstrated early clinical activity. Biomea reported consistent weight reduction across five multiple-ascending-dose cohorts over four weeks, with patients reaching doses as high as 400 mg once daily after a single one-week titration period. The company also characterized tolerability as encouraging. Biomea Fusion Announces Phase 1 Results for BMF-650
• Neutral Sentiment: Management highlighted the potential to separate gastrointestinal side effects from weight loss. The accompanying discussion focused on BMF-650’s potential differentiation from existing GLP-1 therapies, but this remains an early hypothesis requiring additional clinical validation. BMF-650 Phase I Topline Results Transcript
• Negative Sentiment: The shares fell following the Phase 1 readout. Investors may have viewed the four-week, early-stage dataset as insufficient to establish BMF-650’s durability, comparative efficacy, or long-term safety. The stock is also trading near its 52-week low, reflecting substantial skepticism despite the bullish analyst targets. Biomea Reports Phase 1 Weight-Loss Data for BMF-650

Biomea Fusion Company Profile

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes.